<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 15, 1998
ALPHA 1 BIOMEDICALS, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C> <C>
DELAWARE 0-15070 52-1253406
(State or other (Commission File (IRS Employer
jurisdiction of Number) Identification No.)
incorporation)
</TABLE>
6707 Democracy Boulevard
Suite 111
Bethesda, MD 20817
(Address, including Zip Code, of principal executive offices)
Registrant's telephone number, including area code:
301-564-4400
<PAGE> 2
Item 5. Other Events
On May 15, 1998, Alpha 1 Biomedicals, Inc. (the "Company") and
SciClone Pharmaceuticals, Inc. ("SciClone") entered into a First
Amendment Agreement to the Alpha Rights Acquisition Agreement
dated December 17, 1997. The purpose of the First Amendment
Agreement is to provide for the continuation of the sublicense by
SciClone of certain proprietary rights licensed by the Company
from a third party under a license agreement rather than as an
assignment of rights.
Item 7. Financial Statements and Exhibits
(c) Exhibits
Exhibit No. 10.1 - First Amendment Agreement to Alpha Rights
Acquisition Agreement, dated May 15, 1998.
2
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
Date: May 15, 1998 ALPHA 1 BIOMEDICALS, INC.
By: /s/ R.J. Lanham
------------------------
R.J. Lanham
Vice President &
Chief Financial Officer
3
<PAGE> 1
EXHIBIT 10.1
FIRST AMENDMENT AGREEMENT
to
ALPHA RIGHTS ACQUISITION AGREEMENT
This Agreement is entered into as of May 15, 1998, by and between
SciClone Pharmaceuticals, Inc., a California corporation ("SciClone"), and
Alpha 1 Biomedicals, Inc. , a Delaware corporation ("Alpha"), with respect to
the following facts:
RECITALS
A. SciClone and Alpha entered into that certain Alpha Rights
Acquisition Agreement dated as of December 17, 1997 (the "Acquisition
Agreement"), pursuant to which SciClone is to acquire from Alpha specified
rights of Alpha with respect to thymosin alpha 1 ("TA-1"). Terms used in this
Amendment shall have the same meaning as defined in the Acquisition Agreement.
B. SciClone and Alpha had previously entered into that certain
Thymosin Alpha 1 License Agreement dated as of August 19, 1994 (the "1994
Agreement"), pursuant to which Alpha has licensed to SciClone all of Alpha's
rights with respect to the development, manufacture, use, sale and distribution
of TA-1.
C. Pursuant to the 1994 Agreement, Alpha has granted sublicense
rights to SciClone for SciClone to use certain patent rights which are granted
to Alpha from F. Hoffmann-LaRoche, Ltd. ("Roche-Basle"), and Hoffmann LaRoche,
Inc. ("Roche-US"), which sublicense rights are referred to in the Acquisition
Agreement and in this Amendment as the "Alpha Licensed Patent Rights" and the
agreements under which such sublicense rights are granted to Alpha are referred
to in the Acquisition Agreement and in this Agreement as the "Alpha IP Rights
Agreements".
D. As originally contemplated in the Acquisition Agreement, Alpha was
to assign to SciClone the Alpha Licensed Patent Rights and Alpha's rights with
respect to TA-1 under the Alpha IP Rights Agreements, conditioned upon
obtaining consent from Roche-Basle and Roche-US.
E. Roche-Basle and Roche-US have declined to consent to the proposed
assignment by Alpha to SciClone of the Alpha Licensed Patent Rights and Alpha's
rights with respect to TA-1 under the Alpha IP Rights Agreements, and SciClone
and Alpha have ultimately concluded that it is satisfactory to not proceed with
said proposed assignment, but rather to leave in effect the sublicense of said
rights from Alpha to SciClone pursuant to the 1994 Agreement.
F. The parties hereby wish to amend the Acquisition Agreement to
eliminate the provisions applicable to an assignment of the Alpha Licensed
Patent Rights and Alpha's rights with respect to TA-1 under the Alpha IP Rights
Agreement from Alpha to SciClone; and in lieu thereof, the parties wish to
amend the Acquisition Agreement to provide for (a) the continuation of the
sublicensing of the Alpha Licensed Patent Rights from Alpha to SciClone
pursuant to the 1994 Agreement, and (b) the continuation of the 1994 Agreement
in full force and effect for the limited purpose of, and to the limited extent
4
<PAGE> 2
necessary for, a continuation of said sublicensing of the Alpha Licensed Patent
Rights.
WHEREFORE, the parties hereto mutually agree as follows:
1. Clarifications; Amendment of Term "Alpha Rights".
a. Except as otherwise provided in paragraph (b), the
defined term "Alpha Rights" is hereby amended to exclude the Alpha Licensed
Patent Rights and the Alpha IP Rights Agreements.
b. The term "Alpha Rights" shall continue to include the
Alpha Licensed Patent Rights and Alpha's rights with respect to TA-1 under the
Alpha IP Rights Agreements for purposes of (i) Exhibit F attached to the
Acquisition Agreement, (ii) Section 7.2(f) of the Acquisition Agreement, and
(iii) Section 8.1 of the Acquisition Agreement.
2. Consents. The closing condition set forth in Section 7.2(a)
of the Acquisition Agreement is hereby deleted.
3. Limited Continuation of 1994 Agreement. As a modification to
Section 13 of the Acquisition Agreement, the 1994 Agreement will not terminate
as of the Closing of the Acquisition Agreement, but rather, the 1994 Agreement
will continue in effect to the extent as specified in Section 13 of the
Acquisition Agreement, plus also to the limited extent needed for continuing
the sublicense from Alpha to SciClone of the Alpha Licensed Patent Rights and
Alpha's rights with respect to TA-1 under the Alpha IP Rights Agreements, but
without any obligation of SciClone to pay royalties in respect thereof pursuant
to Section 5.1 of the 1994 Agreement.
4. Termination. The date set forth in Section 9.1 of the
Acquisition Agreement is hereby changed to July 31, 1998.
5. General Provisions. The general provisions as set forth in
Section 14 of the Acquisition Agreement shall apply equally to this Amendment.
6. Effect. Except as otherwise expressly set forth in this
Amendment, all of the terms and provisions of the Acquisition Agreement shall
remain in full force and effect.
IN WITNESS WHEREOF, the parties have executed and delivered this Amendment as
of the date set forth above.
SCICLONE:
SciClone Pharmaceuticals, Inc.
a California corporation
By:
---------------------------------
ALPHA:
Alpha 1 Biomedicals, Inc.
a Delaware corporation
By:
---------------------------------
5
